Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The medical content of the claimed warnings is broadly consistent with the provided Eliquis label excerpts (premature discontinuation → thrombotic risk; neuraxial anesthesia/puncture → spinal/epidural hematoma with potential long-term/permanent paralysis). However, the response’s reliance on specific section numbering/citations is not verifiably aligned with the provided label text, so alignment is reduced due to citation/verification issues.
Category Scores
Accurate Statements
ELIQUIS labeling warns that premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.
Supported by the provided excerpt from Warnings and Precautions (premature discontinuation increases thrombotic events).
ELIQUIS labeling warns that when neuraxial anesthesia or spinal/epidural puncture is employed, patients are at risk of developing an epidural or spinal hematoma that can result in long-term or permanent paralysis.
Supported by the provided excerpt from Warnings and Precautions (spinal/epidural anesthesia or puncture risk of spinal/epidural hematoma and potential long-term/permanent paralysis).
Counseling includes not discontinuing ELIQUIS without talking to a physician first, and seeking emergent medical attention if symptoms of spinal/epidural hematoma occur.
Supported by the provided patient counseling excerpts (not to discontinue without physician contact; seek emergent care for symptoms).
Unsupported Statements
The claim is supported specifically by FDA label citations to sections '5.1', '5.3', and '17' with the exact language as presented in the response.
The response text asserts specific section numbers/verified quote placement, but the audit cannot confirm that the cited section numbering and quote attribution are verified against the FDA-approved label beyond the provided excerpt structure. Therefore, citation verifiability is insufficient.
Contradictions
Important Omissions
The response did not explicitly include the additional counseling/warnings nuance present in the provided excerpt (e.g., monitoring for neurological impairment symptoms and/or specific procedural timing guidance in Warnings 5.3 and Dosage 2.4), though these are not required to support the narrow claim. However, they are potentially material if the user expects comprehensive safety coverage rather than the two core warning themes.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Core warning content appears consistent with the provided label excerpts, but the inability to verify the exact FDA label section-number citations in the response increases the risk of reviewer misinterpretation.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Label-citation verification problem: specific section numbers/quote-attribution are not verifiably confirmed from the provided data, even though the warning concepts match the excerpts.
Suggested Improvement
Quote or paraphrase directly from the provided label excerpts without asserting unverified section-number matches, or provide verifiable label section identifiers exactly as shown in the actual FDA-approved label text used for the audit.